The first evidence of this came from the observation that ZNF217 is (directly or indirectly) an ERα target gene, as 17β-estradiol exposure led to ZNF217 mRNA deregulated expression in ER+ breast cancer cells [81]. This evidence concerns the gene ZNF217 and breast carcinoma.